DexComvs.Insulet
DXCM vs PODD · both in Diabetes & metabolic disease, part of the Medicine, pharma & life science value chain: Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring.
DexCom is about 3.4× larger than Insulet by market cap; Insulet trades at the lower P/E (24.8 vs 31.8); year to date, DexCom leads (+27.0% vs −52.7%).
Side by side
| DXCM | PODD | |
|---|---|---|
| Market cap | $31.8B | $9.3B |
| Price | $84.41 | $134.47 |
| Today | +0.1% | +0.1% |
| Return YTD | +27.0% | −52.7% |
| Return 1Y | +27.7% | −57.1% |
| Since June 26, 2026 | +20.3% | −15.0% |
| P/E | 31.8 | 24.8 |
| P/S | 6.4 | 3.1 |
| P/B | 12.1 | 6.2 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
DexComDXCM
Continuous glucose monitoring for people with diabetes: the G-series sensors, and Stelo, which is sold over the counter.
Full DXCM profile →InsuletPODD
Maker of Omnipod, a tubeless insulin pump that handles dosing automatically.
Full PODD profile →More DXCM & PODD comparisons
Other head-to-heads in the Diabetes & metabolic disease segment.